Pleural
Cytoreductive Surgery With or Without HITHOC for Pleural Mesothelioma: A Meta-analysis of Survival and Perioperative Outcomes
Annals of Surgical Oncology 2026 March 16 [Link] Lucas Monteiro Delgado, Rachid Eduardo Noleto da Nobrega Oliveira, Guilherme Franceschini Machado, Luiza Soares Guerra, Cauã de Toledo Corrêa, Mario Claudio Ghefter, Paulo Manuel-Pêgo Fernandes, Marcello Migliore, Ricardo Mingarini Terra, Paula Duarte D’Ambrosio Abstract Background: Pleural mesothelioma (PM) is a rare and aggressive malignancy with limited overall…
Read MoreTGF-β Inhibition Through Combinatory Strategies Suppresses Proliferation and Invasiveness in Malignant Pleural Mesothelioma
International Journal of Molecular Sciences 2026 February 25 [Link] Valeria Ramundo, Maria Luisa Palazzo, Stefania Lignola, Daniela Raimondo, Joanna Kopecka, Elisabetta Aldieri Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor associated with asbestos exposure, which represents a current problem. MPM is characterized by a poor prognosis and an unsatisfactory therapeutic approach. Therefore,…
Read MorePivotal role of long non-coding RNA in the development of new therapeutic approaches for pleural mesothelioma
Discover Oncology 2026 March 12 [Link] Caroline Joseph Kiriacos, Dina M Elkahwagy, Manar Mansour Abstract Pleural mesothelioma is a rare aggressive tumor that affects the parietal layer of the pleura. It constitutes 90% of mesotheliomas. Usually, the diagnosis takes place 30 to 40 years after asbestos exposure. Thus, patients are diagnosed at a very late…
Read MoreMalignant Pleural Mesothelioma (MPM) Evaluation with [11C]-Methionine PET/CT Before and After Talc Pleurodesis
Molecular Imaging and Biology 2026 March 9 [Link] Egesta Lopci, Angelo Castello, Alberto Testori, Emanuele Voulaz, Daoud Rahal 5, Matteo Perrino 6, Alessandro Crepaldi 3, Giorgio Maria Ferraroli 3, Valentina Errico 3, Edoardo Bottoni 3, Marcello Rodari 7, Lorenzo Muraglia 2, Giuseppe Marulli 3 4, Marco Alloisio, Paolo Andrea Zucali Abstract Background: Malignant pleural mesothelioma…
Read MoreGermline genetic testing and privacy concerns in patients with mesothelioma
Genetics in Medicine 2026 March 4 [Link] Owen D Mitchell, Abigail P Sneider, Katie Gilliam, Daniela Del Gaudio, Meghana Gaduraju, Soma Das, Feighanne Hathaway, Darren S Bryan, Sanjukta Tawde, Shelly Galasinski, John Novembre, Anya E R Prince, Jane E Churpek, Hedy L Kindler, Michael W Drazer Abstract Purpose: Mesothelioma, a disease overwhelmingly driven by asbestos…
Read MoreEnhanced nuclear export caused by O-GlcNAcylation of nucleoporins is a potential therapeutic target in mesothelioma
British Journal of Cancer 2026 May [Link] Satomi Mukai, Tatsuhiro Sato, Yasuhiro Kamei, Kagayaki Kato, Emi Mishiro-Sato, Lisa Kondo-Ida, Norikazu Yabuta, Kenzo Hiroshima, Yoshitaka Sekido Abstract Background: Mesothelioma is an aggressive malignancy with limited therapeutic options. Genetic alterations involving the Hippo pathway are commonly observed. O-GlcNAcylation is frequently elevated in cancer and drives tumour progression.…
Read MoreAdvancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles for Mesothelioma Treatment
AAPS PharmSciTech 2026 March 4 [Link] Mural Quadros, Naveen Rajana, Vivek Gupta Abstract Despite advances in mesothelioma treatment, malignant pleural mesothelioma (MPM) continues to present a poor prognosis due to its aggressive progression and resistance to conventional therapies. Current treatment modalities, including surgery, chemotherapy, radiation, and immunotherapy, offer limited efficacy, with a five-year survival rate…
Read MoreEffects of Autophagy Inhibition by SAR405, a Selective VPS34 Inhibitor, on Pleural Mesothelioma Cells
Thoracic Cancer 2026 March [Link] Yoshiki Kuwabara, Kosuke Sakai, Kota Shiraishi, Itsuka Matsumoto, Shigeru Ishii, Shin Yokosuka, Masatoshi Abe, Tomoyuki Takahashi, Yuichiro Kawano, Hiroaki Nishimura, Maiko Toda-Sasaki, Yumiko Kobayashi-Ogawa, Satoshi Kikuchi 1, Yusuke Hirata 1, Hiroyuki Kyoyama, Gaku Moriyama, Nobuyuki Koyama, Kazutsugu Uematsu Abstract Background: Pleural mesothelioma is a highly aggressive malignancy with a poor…
Read MoreMedical thoracoscopy with talc poudrage and indwelling pleural catheter insertion versus medical thoracoscopy with talc poudrage alone for patients with symptomatic malignant pleural effusion (TACTIC): a randomised, controlled phase 3 trial
The Lancet. Respiratory Medicine 2026 April [Link] Alexandra Dipper, Anand Sundaralingam, Emma Hedley, Sharada Gudur, Janet Mills, Sandra Sowden, John P Corcoran, Cyrus Daneshvar, Chris Craig, Andrew J Moore, Alice Milne, Amelia Clive, Rahul Bhatnagar, Mark E Roberts, Thapas Nagarajan, Farheen Kutubudin, Helen Wassal, Moustafa Aboushehata, Sana Iftikhar, Mohammed Haris, Manjumol Abraham, Rajini Sudhir, Rakesh…
Read MoreTargeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma
Cell Death & Disease 2026 February 28 [Link] Sivasundaram Karnan, Akinobu Ota, Muhammad Nazmul Hasan, Hideki Murakami, Md Lutfur Rahman, Md Wahiduzzaman, Md Towhid Ahmed Shihan, Nushrat Jahan, Lam Quang Vu, Ichiro Hanamura, Akihito Inoko, Miho Riku, Hideaki Ito, Yoshifumi Kaneko, Yinzhi Lin, Toshinori Hyodo, Hiroyuki Konishi, Shinobu Tsuzuki, Yoshitaka Hosokawa Abstract Pleural mesothelioma (PM)…
Read More
Skip to content